Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Advanced Proteome Therapeutics Corporation V.APC.H

Alternate Symbol(s):  APTCF

Advanced Proteome Therapeutics Corporation is actively seeking additional funds to advance its core technologies for partnering and other potential revenue streams. It is not engaged in any activity.


TSXV:APC.H - Post by User

Post by jmostockon Oct 23, 2018 10:46am
45 Views
Post# 28855698

Hear me out on this Theory.

Hear me out on this Theory.Maybe I am dilutional here but piece this together.

We have 3 companies in the mix: 1. HeidleBerg (HDL), 2. Magenta 3. APC     The whole magic is putting an AntiBody (ADC) linked with a toxin to destroy a cell, cancerous cells in this scenario.   The antibody is attracted to the cells.    This is what Magenta  supplies (ADC's) and masters in their domain.  Now they needed a company with a great toxin.   This is where HDL comes into the picture.  HDL has amantin from death cap mushrooms.      They discovered amantin destroys cancer cells but needed to find a way to deliver the amantin directly to the cancer cell instead of all cells.    PROBLEM:  How do they join the ADC and Amantin?    Well if you look over HDL site they clearly went out and built their own LINKER Technology.     It was good enough to gain the attention of Magenta and likely showed some success.    Now ENTER THE INTRODUCTION OF APC.   APC is the master of LINKING ADC's and TOXINS via Chemical process.   So hence our partnership with HDL.   HDL wants to test APC's LINKING TECHNOLOGY with AMANTIN and Magenta's ADC.  Basically can APC provide a better consistent drug than our own way of linking.   Bam we have early news that we (APC) performed very well.  Leads me to believe HDL & MAGENTA are saying let's continue to use APC Linker tech and do deeper tests.  By they way HDL, it was so positive that here is your first milestone payment of $125M    
 
And maybe it's not $125M, maybe it's $10M - still shows a signal of this 3 way partnership combo works.   

 Now what's next?     Does the above make sense to anyone else??   jmo (just my opinion)





Bullboard Posts